Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aspects of hormone replacement therapy

C F Holinka1

  • 1R. W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey 08869.

Annals of the New York Academy of Sciences
|September 30, 1994
PubMed
Summary

Estrogen replacement therapy (ERT) offers heart benefits but risks uterine cancer. Adding progestogen protects against uterine cancer but may reduce heart benefits, requiring careful dosing and further research for optimal markers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ovulation inhibition by estetrol in an in vivo model.

Climacteric : the journal of the International Menopause Society·2017
Same author

Estetrol, a pregnancy-specific human steroid, prevents and suppresses mammary tumor growth in a rat model.

Climacteric : the journal of the International Menopause Society·2017
Same author

Estetrol: a unique steroid in human pregnancy.

Climacteric : the journal of the International Menopause Society·2008
Same author

Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model.

Climacteric : the journal of the International Menopause Society·2008
Same author

Preventive effect of oral estetrol in a menopausal hot flush model.

Climacteric : the journal of the International Menopause Society·2008
Same author

Estrogenic uterovaginal effects of oral estetrol in the modified Allen-Doisy test.

Climacteric : the journal of the International Menopause Society·2008

Area of Science:

  • Reproductive Endocrinology
  • Oncology
  • Cardiology

Background:

  • Estrogen replacement therapy (ERT) is associated with significant cardioprotective effects.
  • Unopposed ERT increases the risk of endometrial cancer.
  • Adjunctive progestogen therapy is effective in preventing and treating estrogen-induced endometrial hyperplasia and adenocarcinoma.

Purpose of the Study:

  • To evaluate the protective effects of progestogen against estrogen-induced endometrial hyperplasia/adenocarcinoma.
  • To address concerns regarding the potential attenuation of ERT's cardioprotective effects by adjunctive progestogen.
  • To identify optimal progestogen dosing strategies and reliable biomarkers for endometrial protection.

Main Methods:

  • Review of evidence on the efficacy of progestogen in preventing endometrial cancer.
  • Analysis of clinical trial data using secretory transformation as an endpoint for progestogen efficacy.
  • Discussion of the challenges in correlating endometrial protection with secretory changes.

Main Results:

  • Progestogen effectively protects against estrogen-induced endometrial adenocarcinoma and treats hyperplasia.
  • Concerns exist that progestogen may diminish the cardioprotective benefits of estrogen.
  • Current evidence suggests progestogen is not indicated for hysterectomized women and should be used at the lowest effective dose for others.

Conclusions:

  • The use of adjunctive progestogen requires careful consideration of the balance between endometrial protection and potential cardiovascular effects.
  • Further research is necessary to identify progestogen-regulated markers that accurately predict protection against endometrial cancer.
  • Optimizing progestogen dosage and identifying reliable biomarkers are crucial for safe and effective hormone therapy.

Related Experiment Videos